Spots Global Cancer Trial Database for ofatumumab
Every month we try and update this database with for ofatumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01527149 | Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle... | Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | 18 Years - 70 Years | Roswell Park Cancer Institute | |
| Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation | NCT01455051 | Chronic Lymphoc... | Ofatumumab | 18 Years - 70 Years | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | NCT01263418 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, B-Cel... Lymphoma, Low-G... Lymphoma, Inter... | Ofatumumab | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | NCT01217749 | B-cell Chronic ... Small Lymphocyt... Prolymphocyctic... Richter's Trans... | PCI-32765 ofatumumab | 18 Years - | Pharmacyclics LLC. | |
| Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma | NCT01691807 | Cancer | ofatumumab bendamustine | 18 Years - | Novartis | |
| Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | NCT01190449 | Lymphoma | ofatumumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | NCT01078922 | Non-Hodgkin Lym... | Ofatumumab | 18 Years - | Oncology Specialists, S.C. | |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | NCT03488225 | Acute Lymphobla... B Acute Lymphob... B Acute Lymphob... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 16 Years - | M.D. Anderson Cancer Center | |
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT01243190 | Chronic Lymphoc... | Ofatumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | NCT01458366 | Non-Hodgkin's L... | Bendamustine Ofatumumab Carboplatin Etoposide CT Scan PET Scan Stem Cell Trans... | 18 Years - | Thomas Jefferson University | |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | NCT01352312 | Chronic Lymphoc... B-Cell Non-Hodg... | Bendamustine Pentostatin Ofatumumab | 18 Years - | Thomas Jefferson University | |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | NCT03488225 | Acute Lymphobla... B Acute Lymphob... B Acute Lymphob... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Leucovorin Calc... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 16 Years - | M.D. Anderson Cancer Center | |
| Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients | NCT01613300 | B-Cell Lymphoma... | Ofatumumab | 18 Years - 65 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma | NCT01195766 | Hodgkin Disease | Ofatumumab | 18 Years - 75 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | NCT01659047 | Chronic Lymphoc... | GS-1101 | 18 Years - | Gilead Sciences | |
| Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01310101 | Chronic Lymphoc... | ofatumumab plus... | 18 Years - | Brno University Hospital | |
| Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | NCT01481272 | Diffuse Large B... | Ofatumumab Etoposide Ifosfamid Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Col... | 18 Years - | Polish Lymphoma Research Group | |
| Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients | NCT01481272 | Diffuse Large B... | Ofatumumab Etoposide Ifosfamid Mesna Cytarabine Methotrexate Leukovorin Granulocyte-Col... | 18 Years - | Polish Lymphoma Research Group | |
| Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01310101 | Chronic Lymphoc... | ofatumumab plus... | 18 Years - | Brno University Hospital | |
| Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01014208 | Lymphoma, Large... | OFATUMUMAB + DH... RITUXIMAB + DHA... | 18 Years - | GlaxoSmithKline | |
| Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | NCT00824265 | Leukaemia, Lymp... | OFC Infusion FC infusion | 18 Years - | Novartis | |
| Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) | NCT01108341 | Non-Hodgkin's L... | Bendamustine hy... Ofatumumab | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | NCT01376713 | Stage III Melan... Stage IV Melano... | Ofatumumab Ofatumumab plus... | 18 Years - | Medical University of Vienna | |
| Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL | NCT01612988 | B-cell Chronic ... | BOMP | 18 Years - 80 Years | French Innovative Leukemia Organisation | |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | NCT03136146 | Recurrent Acute... Recurrent Adult... Recurrent Burki... Recurrent Burki... Recurrent Child... Recurrent High ... Refractory Acut... Refractory Burk... Refractory Burk... Refractory High... Refractory Lymp... | Bortezomib Clofarabine Cyclophosphamid... Dexamethasone Etoposide Ofatumumab Pegfilgrastim Rituximab Vincristine Sul... | 15 Years - | M.D. Anderson Cancer Center | |
| Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | NCT00494780 | Lymphoma, Folli... | Ofatumumab Cyclophosphamid... Doxorubicin Vincristine Prednisolone, P... | 18 Years - | GlaxoSmithKline | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | NCT01239394 | Follicular Lymp... Marginal Zone L... Small Lymphocyt... | ofatumumab | 18 Years - | Massachusetts General Hospital | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | NCT00824265 | Leukaemia, Lymp... | OFC Infusion FC infusion | 18 Years - | Novartis | |
| Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | NCT01078922 | Non-Hodgkin Lym... | Ofatumumab | 18 Years - | Oncology Specialists, S.C. | |
| Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy | NCT01077518 | Lymphoma, Folli... | Ofatumumab Bendamustine in... Ofatumumab and ... Bendamustine in... | 18 Years - | Novartis | |
| Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects | NCT01110031 | Leukaemia, Lymp... | Ofatumumab | 18 Years - | GlaxoSmithKline | |
| Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) | NCT00802737 | Leukaemia, Lymp... | Ofatumumab | 18 Years - | GlaxoSmithKline | |
| Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia | NCT00748189 | Leukaemia, Lymp... | chlorambucil, t... ofatumumab (GSK... | 18 Years - | Novartis | |
| Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia | NCT00748189 | Leukaemia, Lymp... | chlorambucil, t... ofatumumab (GSK... | 18 Years - | Novartis | |
| A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01578707 | Relapsed or Ref... Small Lymphocyt... | ofatumumab ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | NCT01361711 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | alemtuzumab ofatumumab biopsy | 18 Years - | Northwestern University | |
| HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | NCT00394836 | Lymphoma, Folli... | Ofatumumab Ofatumumab | 18 Years - | GlaxoSmithKline | |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01024010 | Chronic Lymphoc... Stage 0 Chronic... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Cyclophosphamid... Laboratory Biom... Ofatumumab Pentostatin | 18 Years - | Mayo Clinic | |
| Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | NCT01536067 | Waldenström Mac... | ofatumumab bortezomib laboratory biom... | 18 Years - | Roswell Park Cancer Institute | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01527149 | Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle... | Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | 18 Years - 70 Years | Roswell Park Cancer Institute | |
| Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | NCT01221103 | Lymphoma, Mantl... | Combination of ... | 60 Years - | Southern Europe New Drug Organization | |
| Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | NCT01078922 | Non-Hodgkin Lym... | Ofatumumab | 18 Years - | Oncology Specialists, S.C. | |
| Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | NCT01145209 | Small Lymphocyt... CLL (Chronic Ly... | Fludarabine Pho... Ofatumumab Cyclophosphamid... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| "MIRO" Molecularly Oriented Immuno-radio-therapy | NCT02710643 | Follicular Lymp... Follicular Lymp... Follicular Lymp... | OFATUMUMAB | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab | NCT01123356 | Chronic Lymphoc... | Ofatumumab Lenalidomide | 18 Years - | Medical University of South Carolina | |
| Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | NCT00742144 | Leukaemia, Lymp... | ofatumumab | 20 Years - 79 Years | GlaxoSmithKline | |
| Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) | NCT01187303 | Relapsed NLPHL | Ofatumumab | 18 Years - 75 Years | University of Cologne | |
| Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL | NCT01496976 | Chronic Lymphoc... Small Lymphocyt... | High Dose Methy... Ofatumumab Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| "MIRO" Molecularly Oriented Immuno-radio-therapy | NCT02710643 | Follicular Lymp... Follicular Lymp... Follicular Lymp... | OFATUMUMAB | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT01088048 | Indolent Non-Ho... Chronic Lymphoc... Mantle Cell Lym... | Idelalisib Rituximab Bendamustine Ofatumumab Fludarabine Everolimus Bortezomib Chlorambucil Lenalidomide | 18 Years - | Gilead Sciences | |
| Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL) | NCT00823719 | Lymphoma, Large... | ofatumumab + IC... ofatumumab + DH... | 18 Years - | GlaxoSmithKline | |
| Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL | NCT01217749 | B-cell Chronic ... Small Lymphocyt... Prolymphocyctic... Richter's Trans... | PCI-32765 ofatumumab | 18 Years - | Pharmacyclics LLC. | |
| Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy | NCT01039376 | Leukaemia, Lymp... | Ofatumumab Observation | - | Novartis | |
| Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | NCT01010568 | Chronic Lymphoc... Small Lymphocyt... | Ofatumumab and ... | 18 Years - | Georgetown University | |
| Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | NCT01294579 | Lymphoma, Non-H... | Ofatumumab Bendamustine | 18 Years - | Novartis | |
| Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | NCT01294579 | Lymphoma, Non-H... | Ofatumumab Bendamustine | 18 Years - | Novartis | |
| Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | NCT01190449 | Lymphoma | ofatumumab | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT01363128 | Acute Lymphobla... Adult Acute Lym... Burkitt Leukemi... Burkitt Lymphom... CD20 Positive Childhood Acute... Lymphoblastic L... | Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | - | M.D. Anderson Cancer Center | |
| Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy | NCT01626352 | Diffuse Large B... | Bendamustine Ofatumumab | 70 Years - | SCRI Development Innovations, LLC | |
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT01243190 | Chronic Lymphoc... | Ofatumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia | NCT01848145 | Chronic Lymphoc... | Ofatumumab | 18 Years - | SCRI Development Innovations, LLC | |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | NCT01515176 | Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... | Dinaciclib Laboratory Biom... Ofatumumab Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | NCT01497496 | Chronic Lymphoc... Small Lymphocyt... | High Dose Methy... Ofatumumab Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients | NCT00410163 | Leukaemia, Lymp... | Ofatumumab 500m... Ofatumumab 1000... Fludarabine Cyclophosphamid... | 18 Years - | GlaxoSmithKline | |
| A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) | NCT01580228 | Chronic Lymphoc... | Dinaciclib Ofatumumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | NCT01536067 | Waldenström Mac... | ofatumumab bortezomib laboratory biom... | 18 Years - | Roswell Park Cancer Institute | |
| Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation | NCT01809847 | Chronic Lymphat... | Ofatumumab | 56 Years - | Technische Universität Dresden | |
| Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) | NCT01520922 | Chronic Lymphoc... Leukaemia, Lymp... | Ofatumumab Bendamustine | 18 Years - | Novartis | |
| Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma | NCT01286272 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Grade 3a Follic... | Bendamustine Hy... Bortezomib Fludeoxyglucose... Laboratory Biom... Ofatumumab Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01310101 | Chronic Lymphoc... | ofatumumab plus... | 18 Years - | Brno University Hospital | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia | NCT02388048 | Leukemia, Lymph... | Ibrutinib + ofa... | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant | NCT00622388 | Lymphoma, Large... | Ofatumumab | 18 Years - | GlaxoSmithKline | |
| A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment | NCT01678430 | Chronic Lymphoc... | Ofatumumab Chlorambucil Bendamustine | 18 Years - | University of Liverpool | |
| Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | NCT00742144 | Leukaemia, Lymp... | ofatumumab | 20 Years - 79 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
